Canada: Federal Court Of Appeal Finds Sanofi’s Plavix Patent Valid And Infringed

In Sanofi-Aventis v Apotex Inc, the Federal Court of Appeal1 (FCA) concluded that the Federal Court erred in its judgment (reported here), that Sanofi's Canadian Patent No. 1,336,777 (the '777 Patent) was invalid and consequently allowed Sanofi's action for infringement. This decision is of particular interest for its comments on the promise of the patent, an important but controversial aspect of the utility analysis in Canada.


The '777 Patent is a selection patent. It relates to the active and less toxic enantiomer of a racemate2 known as PCR 4099 which falls within a large genus of racemates claimed in Sanofi's Canadian Patent No. 1,194,875 (the '875 Patent). The bisulfate salt of the enantiomer of the '777 Patent is the active ingredient in the anticoagulant drug PlavixTM.

Apotex had previously sought marketing authorization from Health Canada for a generic version of clopidogrel. Sanofi responded by bringing an application under the Patented Medicines (Notice of Compliance) Regulations, a case which ultimately ended up before the Supreme Court of Canada (SCC). In Apotex Inc v Sanofi-Synthelabo Canada Inc ("Plavix"), the SCC found that Apotex's allegations that the '777 Patent was invalid for anticipation, obviousness and double patenting were not justified.

Apotex subsequently commenced an action in the Federal Court seeking a declaration that the '777 Patent was invalid3. The Federal Court found that the '777 Patent was invalid because the utility of the invention had neither been demonstrated nor soundly predicted as of the filing date of the patent application. A determinative factor in the utility analysis was the Federal Court's conclusion that the '777 Patent promises the use of the invention in humans. This conclusion was reached using inferences based on the wording of the '777 Patent as well as the fact that the genus '875 Patent explicitly mentions use in humans. The Federal Court further went on to consider obviousness, and also found the '777 Patent invalid on this ground.

The FCA Decision

The Canadian courts, including the Federal Court in the present case, have been citing a passage from the FCA decision in Olanzapine for the role of the promise of the patent in a utility analysis. This passage provides that where the patent specification does not promise a specific result, no particular level of utility is required and a mere scintilla of utility will suffice but where the specification sets out an explicit promise, utility will be measured against that promise and the question is whether the invention does what the patent promises it will do. In the present case, the FCA clarified that not every patent contains an explicit promise of a specific result as there is generally no obligation on an inventor to disclose the utility of an invention in a patent. On the other hand, selection patents such as the '777 Patent must set out an explicit promise because of the requirement that both the novelty of the selection and its utility (the advantage secured or the disadvantage avoided by the selection) must be described in the patent.

This decision appears to hold that the mere scintilla standard should be applied unless a skilled person would understand the specification to contain an explicit promise of a specific result. While an inventor who promises more for his invention than required can render his patent invalid by a self-inflicted wound, here the FCA held that the Federal Court erred "in reading into the '777 Patent a promise for use in humans on the basis of inferences, in the absence of language at least as clear and unambiguous as that used to establish the advantages of the selection over the compounds of the genus patent."

The FCA also held that the Federal Court erred in holding that, because the '875 Patent contained a reference to use in humans, the '777 Patent would fail as a selection patent unless an explicit promise for use in humans was also read into it. First, the FCA affirmed a long line of case law holding that is improper to construe a patent with an eye to its validity. Further, the FCA held that it is sufficient that the unexpected advantage of a selection patent is a new and useful improvement on some aspect of the invention described in the genus patent; it need not be an improvement on every aspect.

With respect to obviousness, the FCA held that the Federal Court again erred in holding that the invention was obvious based on the fact that the resolution of the racemate PCR 4099 was obvious to try. It held that the focus of the obviousness analysis in Plavix was not the difficulty in separating the racemates covered by the '875 Patent but rather the unknown properties of the resulting enantiomers, and it was the lack of knowledge as to these properties that led the SCC to hold that it was not self-evident that what was being tried ought to work. As the results to be obtained were unknown, the FCA held that the distance between the common general knowledge and the inventive concept of the '777 Patent could not be bridged by routine experimentation.

Summary and Outlook

In the present case, the FCA stressed that Courts should not strive to find ways to defeat otherwise valid patents. While this suggests that the Canadian courts may be less motivated to read an explicit promise into a patent based on inferences, it remains important (as noted here) to consider the language used in an application to describe a promised utility to ensure it does not elevate the utility beyond that which is supported. The decision also confirms that selection patents must disclose the advantage secured or disadvantage avoided by the selection but clarifies that it is sufficient that this be a new and useful improvement on some aspect of the invention described in the genus patent; not every aspect. Apotex may still seek leave to appeal this decision to the SCC.


1 Reasons for judgment were provided by Pelletier JA, concurred in by Noël JA. Gauthier JA agreed that the appeal should be allowed for the reasons given by Pelletier JA but in concurring reasons commented further on certain issues in respect of utility and obviousness.

2 A racemate is a mixture of equal amounts of two compounds known as enantiomers which differ in structure in that they are mirror images of each other.

3 Sanofi also brought an action alleging Apotex infringed this patent. The two actions were consolidated, and the Federal Court held that the '777 Patent would have been infringed if it were not invalid.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Patricia Folkins
In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.